Identification of a Mesenchymal-related Signature Associated with Clinical Prognosis in Glioma

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2021 Apr 20

PMID 33875619

Citations 4

Authors

Zhengwei Zhang

Jie Chen

Xiuhao Huo

Gang Zong

Kebing Huang

Meng Cheng

Libo Sun

Xiaoyu Yue

Erbao Bian

Bing Zhao

Affiliations

Soon will be listed here.

Abstract

Malignant glioma with a mesenchymal (MES) signature is characterized by shorter survival time due to aggressive dissemination and resistance to chemoradiotherapy. Here, this study used the TCGA database as the training set and the CGGA database as the testing set. Consensus clustering was performed on the two data sets, and it was found that two groups had distinguished prognostic and molecular features. Cox analysis and Lasso regression analysis were used to construct MES signature-based risk score model of glioma. Our results show that MES signature-based risk score model can be used to assess the prognosis of glioma. Three methods (ROC curve analyses, univariate Cox regression analysis, multivariate Cox regression analysis) were used to investigate the prognostic role of texture parameters. The result showed that the MES-related gene signature was proved to be an independent prognostic factor for glioma. Furthermore, functional analysis of the gene related to the risk signature showed that the genes sets were closely related to the malignant process of tumors. Finally, FCGR2A and EHD2 were selected for functional verification. Silencing these two genes inhibited the proliferation, migration and invasion of gliomas and reduced the expression of mesenchymal marker genes. Collectively, MES-related risk signature seems to provide a novel target for predicting the prognosis and treatment of glioma.

Citing Articles

Overexpression of LSR suppresses glioma proliferation and invasion via regulating FOXO3a.

Zhu J, Wang T, Liu X, Lu T, Zhuo J, Li X J Neurooncol. 2025; .

PMID: 39992572 DOI: 10.1007/s11060-025-04976-4.

EHD2 overexpression promotes tumorigenesis and metastasis in triple-negative breast cancer by regulating store-operated calcium entry.

Luan H, Bielecki T, Mohapatra B, Islam N, Mushtaq I, Bhat A Elife. 2023; 12.

PMID: 36625722 PMC: 9988264. DOI: 10.7554/eLife.81288.

Identification of an endoplasmic reticulum stress-related signature associated with clinical prognosis and immune therapy in glioma.

Li L, Yang Z, Zheng Y, Chen Z, Yue X, Bian E BMC Neurol. 2022; 22(1):192.

PMID: 35614390 PMC: 9131635. DOI: 10.1186/s12883-022-02709-y.

Construction of Molecular Subtypes and Related Prognostic and Immune Response Models Based on M2 Macrophages in Glioblastoma.

Xiao K, Zhao S, Yuan J, Pan Y, Song Y, Tang L Int J Gen Med. 2022; 15:913-926.

PMID: 35115817 PMC: 8801375. DOI: 10.2147/IJGM.S343152.

Comprehensive transcriptomic characterization reveals core genes and module associated with immunological changes via 1619 samples of brain glioma.

Zhang Y, Ma W, Fan W, Ren C, Xu J, Zeng F Cell Death Dis. 2021; 12(12):1140.

PMID: 34880206 PMC: 8654825. DOI: 10.1038/s41419-021-04427-8.

References

Chen J, Li Y, Yu T, McKay R, Burns D, Kernie S . A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012; 488(7412):522-6. PMC: 3427400. DOI: 10.1038/nature11287. View

Chai R, Wu F, Wang Q, Zhang S, Zhang K, Liu Y . mA RNA methylation regulators contribute to malignant progression and have clinical prognostic impact in gliomas. Aging (Albany NY). 2019; 11(4):1204-1225. PMC: 6402513. DOI: 10.18632/aging.101829. View

Martinez-Lage M, Lynch T, Bi Y, Cocito C, Way G, Pal S . Immune landscapes associated with different glioblastoma molecular subtypes. Acta Neuropathol Commun. 2019; 7(1):203. PMC: 6902522. DOI: 10.1186/s40478-019-0803-6. View

Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M . Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. PMC: 2818769. DOI: 10.1016/j.ccr.2009.12.020. View

Yoon S, Shim J, Chang J, Moon J, Roh T, Sung K . Tumor Mesenchymal Stem-Like Cell as a Prognostic Marker in Primary Glioblastoma. Stem Cells Int. 2016; 2016:6756983. PMC: 4766342. DOI: 10.1155/2016/6756983. View

Yang F, Liu X, Liu Y, Liu Y, Zhang C, Wang Z . miR-181d/MALT1 regulatory axis attenuates mesenchymal phenotype through NF-κB pathways in glioblastoma. Cancer Lett. 2017; 396:1-9. DOI: 10.1016/j.canlet.2017.03.002. View

Stylli S . Novel Treatment Strategies for Glioblastoma. Cancers (Basel). 2020; 12(10). PMC: 7599818. DOI: 10.3390/cancers12102883. View

Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

Ostrom Q, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y . CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol. 2013; 15 Suppl 2:ii1-56. PMC: 3798196. DOI: 10.1093/neuonc/not151. View

10.

Cheng M, Zhang Z, Ji X, Xu Y, Bian E, Zhao B . Super-enhancers: A new frontier for glioma treatment. Biochim Biophys Acta Rev Cancer. 2020; 1873(2):188353. DOI: 10.1016/j.bbcan.2020.188353. View

11.

Pradella D, Naro C, Sette C, Ghigna C . EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression. Mol Cancer. 2017; 16(1):8. PMC: 5282733. DOI: 10.1186/s12943-016-0579-2. View

12.

Gilder A, Natali L, Van Dyk D, Zalfa C, Banki M, Pizzo D . The Urokinase Receptor Induces a Mesenchymal Gene Expression Signature in Glioblastoma Cells and Promotes Tumor Cell Survival in Neurospheres. Sci Rep. 2018; 8(1):2982. PMC: 5813209. DOI: 10.1038/s41598-018-21358-1. View

13.

Carro M, Lim W, Alvarez M, Bollo R, Zhao X, Snyder E . The transcriptional network for mesenchymal transformation of brain tumours. Nature. 2009; 463(7279):318-25. PMC: 4011561. DOI: 10.1038/nature08712. View

14.

Tu Z, Wu L, Wang P, Hu Q, Tao C, Li K . N6-Methylandenosine-Related lncRNAs Are Potential Biomarkers for Predicting the Overall Survival of Lower-Grade Glioma Patients. Front Cell Dev Biol. 2020; 8:642. PMC: 7390977. DOI: 10.3389/fcell.2020.00642. View

15.

Gutierrez-Erlandsson S, Herrero-Vidal P, Fernandez-Alfara M, Hernandez-Garcia S, Gonzalo-Flores S, Mudarra-Rubio A . R-RAS2 overexpression in tumors of the human central nervous system. Mol Cancer. 2013; 12(1):127. PMC: 3900289. DOI: 10.1186/1476-4598-12-127. View

16.

Liu Y, Chai R, Wang Y, Wang Z, Liu X, Wu F . Amino acid metabolism-related gene expression-based risk signature can better predict overall survival for glioma. Cancer Sci. 2018; 110(1):321-333. PMC: 6317920. DOI: 10.1111/cas.13878. View

17.

Guerra-Rebollo M, Garrido C, Sanchez-Cid L, Soler-Botija C, Meca-Cortes O, Rubio N . Targeting of replicating CD133 and OCT4/SOX2 expressing glioma stem cells selects a cell population that reinitiates tumors upon release of therapeutic pressure. Sci Rep. 2019; 9(1):9549. PMC: 6606606. DOI: 10.1038/s41598-019-46014-0. View

18.

Gao Y, Zhu T, Mao C, Liu Z, Wang Z, Mao X . PPIC, EMP3 and CHI3L1 Are Novel Prognostic Markers for High Grade Glioma. Int J Mol Sci. 2016; 17(11). PMC: 5133809. DOI: 10.3390/ijms17111808. View

19.

Nduom E, Wei J, Yaghi N, Huang N, Kong L, Gabrusiewicz K . PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 2015; 18(2):195-205. PMC: 4724183. DOI: 10.1093/neuonc/nov172. View

20.

Chai R, Zhang K, Wang K, Li G, Huang R, Zhao Z . A novel gene signature based on five glioblastoma stem-like cell relevant genes predicts the survival of primary glioblastoma. J Cancer Res Clin Oncol. 2018; 144(3):439-447. DOI: 10.1007/s00432-017-2572-6. View